FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523704955> ?p ?o ?g. }

• W2523704955 abstract "Abstract Relapsed leukemia is chemotherapy resistant and survival is poor. We recently found that mutations in epigenetic regulators are enriched in relapsed pediatric B-cell acute lymphoblastic leukemia (B-ALL), suggesting that they are associated with clonal survival and chemotherapy resistance. The mutations included loss of function mutations in the epigenetic regulator SETD2, which had not before been described in B-ALL. SETD2 is the only known mammalian Histone 3 Lysine 36 (H3K36) trimethyltransferase and one or two copy loss leads to a global decrease or elimination, respectively, of its chromatin mark, H3K36me3. Using CRISPR/Cas9 to engineer isogenic human and murine leukemia cells, we have demonstrated that SETD2 loss leads to resistance to DNA damaging chemotherapy used in standard ALL therapy, consistent with the gain of SETD2 mutations at relapse. Leukemia cells with SETD2 heterozygous deletion demonstrated a significant increase in IC50 to the DNA damaging anti-metabolites 6-thioguanine (6TG) and cytarabine (AraC), but not the protein synthesis inhibitor L-Asparaginase (Asp). To model the enrichment of SETD2 mutations at relapse, we competed a small population of SETD2 heterozygous cells with isogenic control leukemia cells. Within 3 weeks, treatment with 6TG and AraC, but not Asp or vehicle, led to a dramatic selection of SETD2 heterozygous cells, mimicking the selective pressure of SETD2 clones in patients. Recent reports have shown that H3K36me3is important in the DNA damage response (DDR). Consistent with this, we find that heterozygous SETD2 loss impairs the DDR signaling pathway with attenuated phosphorylation of multiple DDR components, including Chk1 and Chk2, in response to chemotherapy. Consequently, SETD2 heterozygous cells showed an abrogation of the apoptotic response to the DNA damaging chemotherapy agents 6TG and AraC, despite a normal apoptotic response to Asp. In summary, we have demonstrated that SETD2 loss leads to resistance to DNA damaging chemotherapy. The resistance is caused by a failure to trigger DDR signaling and apoptosis after chemotherapy induced DNA damage. These findings identify heterozygous SETD2 lossas a novel mechanism of chemotherapy resistance in leukemia and have implications for therapy selection and novel therapeutic interventions. Disclosures No relevant conflicts of interest to declare." @default.
• W2523704955 created "2016-09-30" @default.
• W2523704955 creator A5011922655 @default.
• W2523704955 creator A5012956545 @default.
• W2523704955 creator A5020161795 @default.
• W2523704955 creator A5022871185 @default.
• W2523704955 creator A5036129568 @default.
• W2523704955 creator A5051532062 @default.
• W2523704955 creator A5055061940 @default.
• W2523704955 creator A5070668676 @default.
• W2523704955 date "2015-12-03" @default.
• W2523704955 modified "2023-09-28" @default.
• W2523704955 title "SETD2 Heterozygous Loss in Leukemia Leads to Chemotherapy Resistance through Attenuation of the DNA Damage Response" @default.
• W2523704955 doi "https://doi.org/10.1182/blood.v126.23.2626.2626" @default.
• W2523704955 hasPublicationYear "2015" @default.
• W2523704955 type Work @default.
• W2523704955 sameAs 2523704955 @default.
• W2523704955 citedByCount "0" @default.
• W2523704955 crossrefType "journal-article" @default.
• W2523704955 hasAuthorship W2523704955A5011922655 @default.
• W2523704955 hasAuthorship W2523704955A5012956545 @default.
• W2523704955 hasAuthorship W2523704955A5020161795 @default.
• W2523704955 hasAuthorship W2523704955A5022871185 @default.
• W2523704955 hasAuthorship W2523704955A5036129568 @default.
• W2523704955 hasAuthorship W2523704955A5051532062 @default.
• W2523704955 hasAuthorship W2523704955A5055061940 @default.
• W2523704955 hasAuthorship W2523704955A5070668676 @default.
• W2523704955 hasConcept C104317684 @default.
• W2523704955 hasConcept C2778461978 @default.
• W2523704955 hasConcept C501734568 @default.
• W2523704955 hasConcept C502942594 @default.
• W2523704955 hasConcept C54355233 @default.
• W2523704955 hasConcept C86803240 @default.
• W2523704955 hasConceptScore W2523704955C104317684 @default.
• W2523704955 hasConceptScore W2523704955C2778461978 @default.
• W2523704955 hasConceptScore W2523704955C501734568 @default.
• W2523704955 hasConceptScore W2523704955C502942594 @default.
• W2523704955 hasConceptScore W2523704955C54355233 @default.
• W2523704955 hasConceptScore W2523704955C86803240 @default.
• W2523704955 hasLocation W25237049551 @default.
• W2523704955 hasOpenAccess W2523704955 @default.
• W2523704955 hasPrimaryLocation W25237049551 @default.
• W2523704955 hasRelatedWork W1993189166 @default.
• W2523704955 hasRelatedWork W2060520682 @default.
• W2523704955 hasRelatedWork W2069411231 @default.
• W2523704955 hasRelatedWork W2137737048 @default.
• W2523704955 hasRelatedWork W2162036790 @default.
• W2523704955 hasRelatedWork W2293890571 @default.
• W2523704955 hasRelatedWork W2530980019 @default.
• W2523704955 hasRelatedWork W2582344225 @default.
• W2523704955 hasRelatedWork W2586831203 @default.
• W2523704955 hasRelatedWork W2886070932 @default.
• W2523704955 hasRelatedWork W2944548570 @default.
• W2523704955 hasRelatedWork W2953919130 @default.
• W2523704955 hasRelatedWork W2980143618 @default.
• W2523704955 hasRelatedWork W2980216545 @default.
• W2523704955 hasRelatedWork W2988782688 @default.
• W2523704955 hasRelatedWork W3110749119 @default.
• W2523704955 hasRelatedWork W3111116407 @default.
• W2523704955 hasRelatedWork W3111462971 @default.
• W2523704955 hasRelatedWork W3111770822 @default.
• W2523704955 hasRelatedWork W3199933518 @default.
• W2523704955 isParatext "false" @default.
• W2523704955 isRetracted "false" @default.
• W2523704955 magId "2523704955" @default.
• W2523704955 workType "article" @default.